1. Zhou NN, Teng XY, Liu DG, Xu R, et al. (2008). [Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients]. Aizheng 27(12):1307-9.